**Dermatitis Policy:**

Idiopathic Ulcerative Dermatitis (UD) is a common, progressive condition in the C57BL/6 and related strains, in which single or multifocal lesions may occur. UD is characterized by pruritus, dermal ulcerations, necrosis, and de-gloving of the skin.

While there are no curative treatments, mild to moderate cases may be controlled with topical therapy, while moderate to severe cases may require systemic treatment or euthanasia. The information below is specific to C57 mice. Other species will be handled on a case-by-case basis.

**Mild cases (single lesion, < 9 mm diameter)**
- Mice identified with UD will have cages flagged with a red “health alert” documentation card and the PI will be notified.
- Mice will be treated 2-3x’s per day by the care staff with a topical solution prescribed by the Attending Veterinarian (AV). Cases will be monitored daily and nails will be clipped as needed.
- Charges may be incurred for applications of topical treatments by care staff.

**Moderate to Severe cases (multiple lesions, total >10 mm)**
- Cases of UD requiring euthanasia are those cases in which the ulceration has exposed the muscle. PIs will receive a 24-48 hour notice to euthanize mice flagged as a severe case. If this time has been exceeded, the care staff will perform euthanasia and charges/mouse or cage may be incurred.
- In cases where euthanasia is not desired due to the value of the mouse, treatment may be attempted using maropitant citrate (Cerenia®) administered at 1 mg/kg IP once daily for 5 - 10 d. by the animal care staff or the investigator. This may result in continual improvement in 94% of cases over a 60 day period. Treatment may be repeated every 60 d as needed. (Williams-Fritze, MJ, et. al., JAALAS Vol 50, No 2; March 2011). Charges for treatment may be incurred for if administered by the animal care staff.
- Treated cases must continue to improve or they AV may order them to be euthanized.

**Social isolation during treatment is allowable at the discretion of the Attending Veterinarian in consultation with the Principal Investigator.**